Joo‐Hee Yi - Concepedia

Concepedia

Author

Joo‐Hee Yi

Bioanalytica (Switzerland)

Also Known As

J. Yi, Joo-Hee Yi, Joo‐Hee Yi

11

Publications

1.2K

Citations

9

H-Index

12

Concepts

All Affiliations

Bioanalytica (Switzerland)The Barbara Ann Karmanos Cancer Institute Sarah Cannon Memorial Sloan Kettering Cancer Center Gene Therapy Laboratory

JY

About

Joo‐Hee Yi is an author at Bioanalytica (Switzerland) specializing in breast cancer, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	153
2	Pharmacology	3	3	153
3	Cancer Therapeutics	3	3	153
4	Immunology	2	2	111
5	Immunotherapy	1	1	42

Joo‐Hee Yi

×

9

Publications

1.2K

Citations

9

H-Index

	Year	Citations
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer Ian E. Krop, Muralidhar Beeram, Shanu Modi, Journal of Clinical Oncology	2010	590
A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans Stephen M. Eppler, Daniel L. Combs, Timothy D. Henry, Clinical Pharmacology & Therapeutics	2002	266
PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine Randall Dere, Joo‐Hee Yi, Corinna Lei, Bioanalysis	2013	71
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer Manish Gupta, Patricia LoRusso, Bei Wang, The Journal of Clinical Pharmacology Metastatic Breast CancerOncologyPharmacokinetic ModelingBreast OncologyMedicine	2011	69
Immunogenicity Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine Montserrat Carrasco‐Triguero, Joo‐Hee Yi, Randall Dere, Bioanalysis	2013	55
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer Dan Lu, Amita Joshi, Bei Wang, Clinical Pharmacokinetics Breast OncologyMultiple-analyte Pharmacokinetic ModelPharmacokinetic ModelingMedicineClearance Pathways	2013	42
Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer Dan Lu, Howard A. Burris, Bei Wang, Current Drug Metabolism Metastatic Breast CancerOncologyBreast OncologyMedicineImmunology	2012	42
Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Manish Gupta, Bei Wang, Timothy J. Carrothers, Clinical Pharmacology in Drug Development	2013	39
Overcoming Soluble Target Interference in An Anti-Therapeutic Antibody Screening Assay For An Antibody–Drug Conjugate Therapeutic Montserrat Carrasco‐Triguero, Connie Mahood, Marija Milojic-Blair, Bioanalysis	2012	33

Page 1